{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:18:27Z","timestamp":1788524307573,"version":"build-2803163510"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2018-NR031048"],"award-info":[{"award-number":["RS-2018-NR031048"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2024-00352291"],"award-info":[{"award-number":["RS-2024-00352291"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02601-y","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T14:28:35Z","timestamp":1773239315000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer"],"prefix":"10.1038","volume":"11","author":[{"given":"Jung","family":"Yoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go Woon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Hyun","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaewook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enzhi","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Wu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Yeon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junjeong","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuglae","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-4415","authenticated-orcid":false,"given":"So Hee","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"2601_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray, F. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 74, 229\u2013263 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"2601_CR2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.semcancer.2021.08.011","volume":"77","author":"C Marchetti","year":"2021","unstructured":"Marchetti, C. et al. Chemotherapy resistance in epithelial ovarian cancer: mechanisms and emerging treatments. Semin Cancer Biol. 77, 144\u2013166 (2021).","journal-title":"Semin Cancer Biol."},{"key":"2601_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-01967-3","volume":"23","author":"L Wang","year":"2024","unstructured":"Wang, L. et al. Drug resistance in ovarian cancer: from mechanism to clinical trial. Mol. Cancer 23, 66 (2024).","journal-title":"Mol. Cancer"},{"key":"2601_CR4","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jamaoncol.2023.0197","volume":"9","author":"DL Richardson","year":"2023","unstructured":"Richardson, D. L., Eskander, R. N. & O\u2019Malley, D. M. Advances in ovarian cancer care and unmet treatment needs for patients with platinum resistance: a narrative review. JAMA Oncol. 9, 851\u2013859 (2023).","journal-title":"JAMA Oncol."},{"key":"2601_CR5","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine, E. et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J. Clin. Oncol. 32, 1302\u20131308 (2014).","journal-title":"J. Clin. Oncol."},{"key":"2601_CR6","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","volume":"32","author":"KN Moore","year":"2021","unstructured":"Moore, K. N. et al. Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I. Ann. Oncol. 32, 757\u2013765 (2021).","journal-title":"Ann. Oncol."},{"key":"2601_CR7","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","volume":"163","author":"S Gaillard","year":"2021","unstructured":"Gaillard, S. et al. Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL). Gynecol. Oncol. 163, 237\u2013245 (2021).","journal-title":"Gynecol. Oncol."},{"key":"2601_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S1470-2045(24)00674-0","volume":"26","author":"AM Oza","year":"2025","unstructured":"Oza, A. M. et al. Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial. Lancet Oncol. 26, 249\u2013264 (2025).","journal-title":"Lancet Oncol."},{"key":"2601_CR9","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3802\/jgo.2012.23.3.182","volume":"23","author":"MG Kim","year":"2012","unstructured":"Kim, M. G. et al. The relationship between cisplatin resistance and histone deacetylase isoform overexpression in epithelial ovarian cancer cell lines. J. Gynecol. Oncol. 23, 182\u2013189 (2012).","journal-title":"J. Gynecol. Oncol."},{"key":"2601_CR10","doi-asserted-by":"publisher","first-page":"788","DOI":"10.4161\/cbt.10.8.12913","volume":"10","author":"S Hu","year":"2010","unstructured":"Hu, S. et al. Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol. Ther. 10, 788\u2013795 (2010).","journal-title":"Cancer Biol. Ther."},{"key":"2601_CR11","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1038\/s41418-024-01257-x","volume":"31","author":"B Zhang","year":"2024","unstructured":"Zhang, B. et al. Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16\/TOP2A axis. Cell Death Differ. 31, 309\u2013321 (2024).","journal-title":"Cell Death Differ."},{"key":"2601_CR12","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1002\/pros.24706","volume":"84","author":"LK Brown","year":"2024","unstructured":"Brown, L. K. et al. Co-targeting SKP2 and KDM5B inhibits prostate cancer progression by abrogating AKT signaling with induction of senescence and apoptosis. Prostate 84, 877\u2013887 (2024).","journal-title":"Prostate"},{"key":"2601_CR13","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1038\/s41417-022-00584-w","volume":"30","author":"E Di Nisio","year":"2023","unstructured":"Di Nisio, E. et al. A truncated and catalytically inactive isoform of KDM5B histone demethylase accumulates in breast cancer cells and regulates H3K4 tri-methylation and gene expression. Cancer Gene Ther. 30, 822\u2013832 (2023).","journal-title":"Cancer Gene Ther."},{"key":"2601_CR14","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.7150\/ijbs.25881","volume":"14","author":"W Xu","year":"2018","unstructured":"Xu, W. et al. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance. Int J. Biol. Sci. 14, 1122\u20131132 (2018).","journal-title":"Int J. Biol. Sci."},{"key":"2601_CR15","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1007\/s13277-014-2859-z","volume":"36","author":"L Wang","year":"2015","unstructured":"Wang, L., Mao, Y., Du, G., He, C. & Han, S. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer. Tumor Biol. 36, 2465\u20132472 (2015).","journal-title":"Tumor Biol."},{"key":"2601_CR16","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1038\/s12276-022-00902-0","volume":"54","author":"J Yoo","year":"2022","unstructured":"Yoo, J. et al. Drawing a line between histone demethylase KDM5A and KDM5B: their roles in development and tumorigenesis. Exp. Mol. Med. 54, 2107\u20132117 (2022).","journal-title":"Exp. Mol. Med."},{"key":"2601_CR17","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1096\/fasebj.14.1.6","volume":"14","author":"M Camps","year":"2000","unstructured":"Camps, M., Nichols, A. & Arkinstall, S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 14, 6\u201316 (2000).","journal-title":"FASEB J."},{"key":"2601_CR18","doi-asserted-by":"publisher","first-page":"7257","DOI":"10.1200\/JCO.2005.02.2541","volume":"23","author":"NL Sieben","year":"2005","unstructured":"Sieben, N. L. et al. Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors. J. Clin. Oncol. 23, 7257\u20137264 (2005).","journal-title":"J. Clin. Oncol."},{"key":"2601_CR19","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-025-03722-0","volume":"25","author":"Y Xiong","year":"2025","unstructured":"Xiong, Y. et al. DUSP4 inhibited tumor cell proliferation by downregulating glycolysis via p-ERK\/p-PGK1 signaling in ovarian cancer. Cancer Cell Int. 25, 87 (2025).","journal-title":"Cancer Cell Int."},{"key":"2601_CR20","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1038\/nm.2795","volume":"18","author":"JM Balko","year":"2012","unstructured":"Balko, J. M. et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance. Nat. Med. 18, 1052\u20131059 (2012).","journal-title":"Nat. Med."},{"key":"2601_CR21","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.1158\/0008-5472.CAN-13-1385","volume":"73","author":"JM Balko","year":"2013","unstructured":"Balko, J. M. et al. Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. Cancer Res. 73, 6346\u20136358 (2013).","journal-title":"Cancer Res."},{"key":"2601_CR22","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1038\/sj.onc.1207740","volume":"23","author":"JE Armes","year":"2004","unstructured":"Armes, J. E. et al. Candidate tumor-suppressor genes on chromosome arm 8p in early-onset and high-grade breast cancers. Oncogene 23, 5697\u20135702 (2004).","journal-title":"Oncogene"},{"key":"2601_CR23","doi-asserted-by":"publisher","first-page":"1689","DOI":"10.1158\/0008-5472.CAN-09-3218","volume":"70","author":"A Waha","year":"2010","unstructured":"Waha, A. et al. Epigenetic downregulation of mitogen-activated protein kinase phosphatase MKP-2 relieves its growth suppressive activity in glioma cells. Cancer Res. 70, 1689\u20131699 (2010).","journal-title":"Cancer Res."},{"key":"2601_CR24","doi-asserted-by":"publisher","first-page":"2773","DOI":"10.1038\/onc.2009.135","volume":"28","author":"D Chitale","year":"2009","unstructured":"Chitale, D. et al. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene 28, 2773\u20132783 (2009).","journal-title":"Oncogene"},{"key":"2601_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112445","volume":"42","author":"L Zhou","year":"2023","unstructured":"Zhou, L. et al. DUSP4 promotes esophageal squamous cell carcinoma progression by dephosphorylating HSP90b. Cell Rep. 42, 112445 (2023).","journal-title":"Cell Rep."},{"key":"2601_CR26","doi-asserted-by":"publisher","first-page":"6146","DOI":"10.3390\/molecules27196146","volume":"27","author":"MS Al-Mutairi","year":"2022","unstructured":"Al-Mutairi, M. S. & Habashy, H. O. DUSP4 silencing enhances the sensitivity of breast cancer cells to doxorubicin through the activation of the JNK\/c-Jun signalling pathway. Molecules 27, 6146 (2022).","journal-title":"Molecules"},{"key":"2601_CR27","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1006\/bbrc.2001.4243","volume":"280","author":"MT Yip-Schneider","year":"2001","unstructured":"Yip-Schneider, M. T., Lin, A. & Marshall, M. S. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2. Biochem. Biophys. Res. Commun. 280, 992\u2013997 (2001).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2601_CR28","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12929-023-00985-5","volume":"30","author":"J Mandal","year":"2023","unstructured":"Mandal, J., Yu, Z. C., Shih, I. M. & Wang, T. L. ARID1A loss activates MAPK signaling via DUSP4 downregulation. J. Biomed. Sci. 30, 94 (2023).","journal-title":"J. Biomed. Sci."},{"key":"2601_CR29","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1158\/1541-7786.MCR-19-0530","volume":"18","author":"A Buensuceso","year":"2020","unstructured":"Buensuceso, A., Ramos-Valdes, Y., DiMattia, G. E. & Shepherd, T. G. AMPK-independent LKB1 activity is required for efficient epithelial ovarian cancer metastasis. Mol. Cancer Res. 18, 488\u2013500 (2020).","journal-title":"Mol. Cancer Res."},{"key":"2601_CR30","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3390\/cells11050851","volume":"11","author":"Y Li","year":"2022","unstructured":"Li, Y., Li, S. & Wu, H. Ubiquitination-proteasome system (UPS) and autophagy two main protein degradation machineries in response to cell stress. Cells 11, 851 (2022).","journal-title":"Cells"},{"key":"2601_CR31","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1007\/s12272-020-01281-8","volume":"43","author":"J Park","year":"2020","unstructured":"Park, J., Cho, J. & Song, E. J. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch. Pharm. Res. 43, 1144\u20131161 (2020).","journal-title":"Arch. Pharm. Res."},{"key":"2601_CR32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","volume":"5","author":"L Deng","year":"2020","unstructured":"Deng, L., Meng, T., Chen, L., Wei, W. & Wang, P. The role of ubiquitination in tumorigenesis and targeted drug discovery. Signal Transduct. Target Ther. 5, 11 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"2601_CR33","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1349-7006.2010.01801.x","volume":"102","author":"M Ibusuki","year":"2011","unstructured":"Ibusuki, M., Yamamoto, Y., Shinriki, S., Ando, Y. & Iwase, H. Reduced expression of ubiquitin ligase FBXW7 mRNA is associated with poor prognosis in breast cancer patients. Cancer Sci. 102, 439\u2013445 (2011).","journal-title":"Cancer Sci."},{"key":"2601_CR34","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/ijc.24879","volume":"126","author":"M Iwatsuki","year":"2010","unstructured":"Iwatsuki, M. et al. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J. Cancer 126, 1828\u20131837 (2010).","journal-title":"Int J. Cancer"},{"key":"2601_CR35","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1002\/stem.2668","volume":"35","author":"D Izumi","year":"2017","unstructured":"Izumi, D. et al. Colorectal cancer stem cells acquire chemoresistance through the upregulation of F-Box\/WD repeat-containing protein 7 and the consequent degradation of c-Myc. Stem Cells 35, 2027\u20132036 (2017).","journal-title":"Stem Cells"},{"key":"2601_CR36","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/nature09779","volume":"471","author":"IE Wertz","year":"2011","unstructured":"Wertz, I. E. et al. Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature 471, 110\u2013114 (2011).","journal-title":"Nature"},{"key":"2601_CR37","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1172\/JCI85747","volume":"126","author":"Q Wang","year":"2016","unstructured":"Wang, Q. et al. Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis. J. Clin. Invest. 126, 2205\u20132220 (2016).","journal-title":"J. Clin. Invest."},{"key":"2601_CR38","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.celrep.2017.09.072","volume":"21","author":"L Novellasdemunt","year":"2017","unstructured":"Novellasdemunt, L. et al. USP7 is a tumor-specific WNT activator for APC-mutated colorectal cancer by mediating beta-catenin deubiquitination. Cell Rep. 21, 612\u2013627 (2017).","journal-title":"Cell Rep."},{"key":"2601_CR39","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/mc.23792","volume":"63","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. KDM1A\/LSD1 inhibition enhances chemotherapy response in ovarian cancer. Mol. Carcinog. 63, 2026\u20132039 (2024).","journal-title":"Mol. Carcinog."},{"key":"2601_CR40","first-page":"917","volume":"41","author":"DH Lu","year":"2019","unstructured":"Lu, D. H. et al. Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial\u2011mesenchymal transition. Oncol. Rep. 41, 917\u2013927 (2019).","journal-title":"Oncol. Rep."},{"key":"2601_CR41","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.bbrc.2020.01.150","volume":"524","author":"J Shen","year":"2020","unstructured":"Shen, J., Hong, L. & Chen, L. Ubiquitin-specific protease 14 regulates ovarian cancer cisplatin-resistance by stabilizing BCL6 oncoprotein. Biochem. Biophys. Res. Commun. 524, 683\u2013688 (2020).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2601_CR42","doi-asserted-by":"publisher","first-page":"e31601","DOI":"10.1371\/journal.pone.0031601","volume":"7","author":"XH Yang","year":"2012","unstructured":"Yang, X. H. et al. XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PLoS One 7, e31601 (2012).","journal-title":"PLoS One"},{"key":"2601_CR43","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/0092-8674(94)90518-5","volume":"78","author":"DE Fisher","year":"1994","unstructured":"Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell 78, 539\u2013542 (1994).","journal-title":"Cell"},{"key":"2601_CR44","doi-asserted-by":"publisher","first-page":"201367","DOI":"10.4061\/2010\/201367","volume":"2010","author":"A Basu","year":"2010","unstructured":"Basu, A. & Krishnamurthy, S. Cellular responses to Cisplatin-induced DNA damage. J. Nucleic Acids 2010, 201367 (2010).","journal-title":"J. Nucleic Acids"},{"key":"2601_CR45","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.3390\/ijms21072346","volume":"21","author":"J Yue","year":"2020","unstructured":"Yue, J. & Lopez, J. M. Understanding MAPK Signaling Pathways in Apoptosis. Int. J. Mol. Sci. 21, 2346 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2601_CR46","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/s41416-019-0673-5","volume":"122","author":"A Gupta","year":"2020","unstructured":"Gupta, A. et al. Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma. Br. J. Cancer 122, 506\u2013516 (2020).","journal-title":"Br. J. Cancer"},{"key":"2601_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-022-01542-y","volume":"24","author":"A Hanna","year":"2022","unstructured":"Hanna, A. et al. Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer. Breast Cancer Res. 24, 51 (2022).","journal-title":"Breast Cancer Res."},{"key":"2601_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101052","volume":"73","author":"SH Hao","year":"2024","unstructured":"Hao, S. H. et al. Dual specific phosphatase 4 suppresses ferroptosis and enhances sorafenib resistance in hepatocellular carcinoma. Drug Resist. Updat. 73, 101052 (2024).","journal-title":"Drug Resist. Updat."},{"key":"2601_CR49","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1002\/jcb.30078","volume":"122","author":"T Varela","year":"2021","unstructured":"Varela, T., Conceicao, N., Laize, V. & Cancela, M. L. Transcriptional regulation of human DUSP4 gene by cancer-related transcription factors. J. Cell Biochem. 122, 1556\u20131566 (2021).","journal-title":"J. Cell Biochem."},{"key":"2601_CR50","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/35107009","volume":"414","author":"P Nash","year":"2001","unstructured":"Nash, P. et al. Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature 414, 514\u2013521 (2001).","journal-title":"Nature"},{"key":"2601_CR51","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1126\/science.1065203","volume":"294","author":"DM Koepp","year":"2001","unstructured":"Koepp, D. M. et al. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294, 173\u2013177 (2001).","journal-title":"Science"},{"key":"2601_CR52","doi-asserted-by":"publisher","first-page":"13224","DOI":"10.1074\/jbc.AC119.008483","volume":"294","author":"V Tripathi","year":"2019","unstructured":"Tripathi, V. et al. Abrogation of FBW7alpha-dependent p53 degradation enhances p53\u2019s function as a tumor suppressor. J. Biol. Chem. 294, 13224\u201313232 (2019).","journal-title":"J. Biol. Chem."},{"key":"2601_CR53","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S1097-2765(03)00287-9","volume":"12","author":"M Welcker","year":"2003","unstructured":"Welcker, M. et al. Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol. Cell 12, 381\u2013392 (2003).","journal-title":"Mol. Cell"},{"key":"2601_CR54","doi-asserted-by":"publisher","first-page":"9085","DOI":"10.1073\/pnas.0402770101","volume":"101","author":"M Welcker","year":"2004","unstructured":"Welcker, M. et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc. Natl. Acad. Sci. USA 101, 9085\u20139090 (2004).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2601_CR55","doi-asserted-by":"publisher","first-page":"D1083","DOI":"10.1093\/nar\/gkaa968","volume":"49","author":"A Luna","year":"2021","unstructured":"Luna, A. et al. CellMiner cross-database (CellMinerCDB) version 1.2: exploration of patient-derived cancer cell line pharmacogenomics. Nucleic Acids Res. 49, D1083\u2013D1093 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2601_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101151","volume":"77","author":"Y Xue","year":"2024","unstructured":"Xue, Y. et al. CYP1B1 promotes PARPi-resistance via histone H1.4 interaction and increased chromatin accessibility in ovarian cancer. Drug Resist. Updat. 77, 101151 (2024).","journal-title":"Drug Resist. Updat."},{"key":"2601_CR57","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.ccell.2018.10.014","volume":"34","author":"K Hinohara","year":"2018","unstructured":"Hinohara, K. et al. KDM5 histone demethylase activity links cellular transcriptomic heterogeneity to therapeutic resistance. Cancer Cell 34, 939\u2013953 e939 (2018).","journal-title":"Cancer Cell"},{"key":"2601_CR58","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1158\/0008-5472.CAN-15-1846","volume":"76","author":"N Hijiya","year":"2016","unstructured":"Hijiya, N. et al. Genomic loss of DUSP4 contributes to the progression of intraepithelial neoplasm of pancreas to invasive carcinoma. Cancer Res. 76, 2612\u20132625 (2016).","journal-title":"Cancer Res."},{"key":"2601_CR59","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1016\/j.molcel.2022.02.004","volume":"82","author":"D Sherpa","year":"2022","unstructured":"Sherpa, D., Chrustowicz, J. & Schulman, B. A. How the ends signal the end: regulation by E3 ubiquitin ligases recognizing protein termini. Mol. Cell 82, 1424\u20131438 (2022).","journal-title":"Mol. Cell"},{"key":"2601_CR60","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1126\/science.aax3769","volume":"366","author":"C Pohl","year":"2019","unstructured":"Pohl, C. & Dikic, I. Cellular quality control by the ubiquitin-proteasome system and autophagy. Science 366, 818\u2013822 (2019).","journal-title":"Science"},{"key":"2601_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-020-01262-x","volume":"19","author":"T Sun","year":"2020","unstructured":"Sun, T., Liu, Z. & Yang, Q. The role of ubiquitination and deubiquitination in cancer metabolism. Mol. Cancer 19, 146 (2020).","journal-title":"Mol. Cancer"},{"key":"2601_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13525","volume":"7","author":"C Han","year":"2016","unstructured":"Han, C. et al. Amplification of USP13 drives ovarian cancer metabolism. Nat. Commun. 7, 13525 (2016).","journal-title":"Nat. Commun."},{"key":"2601_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-020-2519-8","volume":"11","author":"C Hu","year":"2020","unstructured":"Hu, C. et al. The USP10-HDAC6 axis confers cisplatin resistance in non-small cell lung cancer lacking wild-type p53. Cell Death Dis. 11, 328 (2020).","journal-title":"Cell Death Dis."},{"key":"2601_CR64","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202002680","volume":"7","author":"Z Zhao","year":"2020","unstructured":"Zhao, Z. et al. USP38 couples histone ubiquitination and methylation via KDM5B to resolve inflammation. Adv. Sci. 7, 2002680 (2020).","journal-title":"Adv. Sci."},{"key":"2601_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-022-04800-1","volume":"13","author":"B Chen","year":"2022","unstructured":"Chen, B. et al. KDM5B promotes tumorigenesis of Ewing sarcoma via FBXW7\/CCNE1 axis. Cell Death Dis. 13, 354 (2022).","journal-title":"Cell Death Dis."},{"key":"2601_CR66","doi-asserted-by":"publisher","first-page":"8629","DOI":"10.3390\/ijms21228629","volume":"21","author":"SB Shin","year":"2020","unstructured":"Shin, S. B., Kim, C. H., Jang, H. R. & Yim, H. Combination of inhibitors of USP7 and PLK1 has a strong synergism against paclitaxel resistance. Int. J. Mol. Sci. 21, 8629 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"2601_CR67","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s10637-020-00951-0","volume":"38","author":"H Chen","year":"2020","unstructured":"Chen, H. et al. Ubiquitin-specific protease 7 is a druggable target that is essential for pancreatic cancer growth and chemoresistance. Invest. N. Drugs 38, 1707\u20131716 (2020).","journal-title":"Invest. N. Drugs"},{"key":"2601_CR68","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan, D. et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22, 345\u2013358 (2012).","journal-title":"Cancer Cell"},{"key":"2601_CR69","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl7872","volume":"8","author":"M Welcker","year":"2022","unstructured":"Welcker, M. et al. Two diphosphorylated degrons control c-Myc degradation by the Fbw7 tumor suppressor. Sci. Adv. 8, eabl7872 (2022).","journal-title":"Sci. Adv."},{"key":"2601_CR70","doi-asserted-by":"publisher","first-page":"7568","DOI":"10.1016\/j.cell.2024.10.012","volume":"187","author":"S Cao","year":"2024","unstructured":"Cao, S. et al. Recognition of BACH1 quaternary structure degrons by two F-box proteins under oxidative stress. Cell 187, 7568\u20137584 e7522 (2024).","journal-title":"Cell"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02601-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02601-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02601-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T16:03:04Z","timestamp":1773244984000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02601-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2601"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02601-y","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"89"}}